Unlock instant, AI-driven research and patent intelligence for your innovation.
Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune and cardiovascular disorders
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
An autoimmune disease, eosinophilic technology, applied in cardiovascular system diseases, cytokines/lymphokines/interferons, anti-inflammatory agents, etc.
Inactive Publication Date: 2012-01-04
特拉维夫医学中心医学研究,基础设施及健康服务基金
View PDF3 Cites 3 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
The eotaxin-3 gene is close to the eotaxin-2 gene on chromosome 7, but shares only 33% homology with it
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0152] Example 1: Specificity and anti-inflammatory effects of anti-eotaxin-2 mAb (D8)
[0153] Multiple anti-eotaxin-2 murine monoclonal antibodies (mAbs) were prepared as described above.
[0224] Adjuvantarthritis was induced in Lewis mice (6-week-old Lewis mice obtained from Harlan, Israel) by injection of incomplete Freund's adjuvant. Incomplete Freund's adjuvant was used to inactivate Mycobacteriumtuberculosis (Difco, Detroit, MI) by heat in mineral oil at a concentration of 10 mg / ml. 100 μl of adjuvant was injected subcutaneously into the tail of mice. Arthritis developed 10 days after injection.
[0226] Mice (8 in each group) were injected intraperitoneally (IP) with 3 monoclonal antibodies against eotaxin-2, (D8, G8, G7) 3X / week. All mice in the control group (non-specific) were treated with IgG or PBS. Injections were performed on the third day after adjuvant administration, three times...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Property
Measurement
Unit
weight
aaaaa
aaaaa
Login to View More
Abstract
The present invention is based on the finding that inhibition of eotaxin-2 by polyclonal or monoclonal antibodies, has a significant protective effect in animal models of inflammatory diseases such as rheumatoid arthritis, experimental autoimmune encephalomyelitis (EAE), colitis, diabetes, and atherosclerosis. The invention thus provides pharmaceutical compositions comprising specific anti-eotaxin 2 antibodies for use alone or in combination with other therapeutic agents in the treatment of inflammatory, autoimmune and cardiovascular diseases. The invention also provides specific anti-eotaxin-2 monoclonal antibodies, and methods of treatment utilizing the antibodies of the invention.
Description
technical field [0001] The invention relates to the application of eotaxin-2 (CCL24) inhibitors in the treatment of inflammation, autoimmune diseases and cardiovascular diseases, especially the polyclonal or monoclonal anti-eotaxin-2 Antibody. Background technique [0002] Inflammatory chemokines are small cytokines that act as leukocyte chemokines, coordinating the balanced trafficking of cells in the body and the restoration of cell populations at sites of inflammation. Chemokine dysregulation has a broad role in diseases involving the human immune system including inflammatory and autoimmune diseases (1). [0003] The human eotaxin family includes 3 cytokine classes known to belong to the CC chemokine family: [0004] Eotaxin 1 (hypersensitive response eotaxin protein 1, also known as eotaxin or chemokine (C-C motif) ligand 11 (CCL11)) Known Selective recovery of eosinophils by induction of chemotaxis, involved in allergic responses. [0005] Eotaxin 2 (allergic respo...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More